Key points from article :
Robust reductions in key biomarkers of liver damage, ALT and AST were reported.
Reduction in glucose and trend towards bodyweight reduction.
CB4211 was well-tolerated and appeared safe with no serious adverse events.
Both the CB4211 and placebo groups had substantial reductions in liver fat content.
Dr. Rohit Loomba stated, “Demonstrating significant reductions of this magnitude in both serum ALT and AST relative to placebo suggests potential liver health improvements in patients with NASH."
The Phase 1a stage of the study was a single ascending dose and multiple ascending dose assessment in 65 healthy adults.
Exploratory endpoints of changes in liver fat, body weight, and biomarkers relevant to nonalcoholic steatohepatitis (NASH), obesity, and metabolic disease.
The company plans to present additional results and analyses at a future scientific meeting.
Dr. Joseph Sarret, “These impressive results validate using the mitochondrial genome as a valuable source to treat serious systemic diseases.”
